Why the study?
Conflicting evidence exists regarding cardiovascular disease risk in NAFLD, data are lacking on post-CVD mortality, and life expectancy in NAFLD has not been studied.
Does NAFLD increase the risk of cardiovascular disease and reduce life expectancy compared to the general population?
Population
10,023 NAFLD patients without baseline CVD and 96,313 matched controls in Sweden
Comparison
NAFLD diagnosis vs matched general population controls
Design
Nationwide population-based matched cohort study
Authors
Loading...
NAFLD may warrant closer CVD monitoring; leaves open whether it independently drives mortality or requires specific interventions.
Does NAFLD increase the risk of cardiovascular disease and reduce life expectancy compared to the general population?
NAFLD is associated with a 2.6-fold higher risk of incident CVD and a 2.8-year reduction in life expectancy, highlighting the need for cardiovascular risk management in this population.
Shang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: